JP2025503521A - ニコチンアミドｎ－メチルトランスフェラーゼの二環式阻害剤、その組成物および使用 - Google Patents

ニコチンアミドｎ－メチルトランスフェラーゼの二環式阻害剤、その組成物および使用 Download PDF

Info

Publication number
JP2025503521A
JP2025503521A JP2024538726A JP2024538726A JP2025503521A JP 2025503521 A JP2025503521 A JP 2025503521A JP 2024538726 A JP2024538726 A JP 2024538726A JP 2024538726 A JP2024538726 A JP 2024538726A JP 2025503521 A JP2025503521 A JP 2025503521A
Authority
JP
Japan
Prior art keywords
compound
alkyl
unsubstituted
cancer
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503521A5 (https=
Inventor
ディー シェア，マシュー
バローズ，ロバート
エドワード ジェフリーズ，ダニエル
ヴィシュ，マヘシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2025503521A publication Critical patent/JP2025503521A/ja
Publication of JP2025503521A5 publication Critical patent/JP2025503521A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024538726A 2021-12-31 2022-12-23 ニコチンアミドｎ－メチルトランスフェラーゼの二環式阻害剤、その組成物および使用 Pending JP2025503521A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163295657P 2021-12-31 2021-12-31
US63/295,657 2021-12-31
PCT/US2022/053976 WO2023129512A1 (en) 2021-12-31 2022-12-23 Bicyclic inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2025503521A true JP2025503521A (ja) 2025-02-04
JP2025503521A5 JP2025503521A5 (https=) 2025-12-23

Family

ID=87000165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538726A Pending JP2025503521A (ja) 2021-12-31 2022-12-23 ニコチンアミドｎ－メチルトランスフェラーゼの二環式阻害剤、その組成物および使用

Country Status (5)

Country Link
US (1) US20250368638A1 (https=)
EP (1) EP4456892A4 (https=)
JP (1) JP2025503521A (https=)
CN (1) CN119110724A (https=)
WO (1) WO2023129512A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163683A1 (en) 2020-02-14 2021-08-19 President And Fellows Of Harvard College Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof
WO2025129168A1 (en) * 2023-12-15 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Triazolone inhibitors of nicotinamide n-methyltransferase and their therapeutic uses
TW202545926A (zh) 2024-01-12 2025-12-01 瑞典商阿斯特捷利康公司 作為菸鹼醯胺ｎ—甲基轉移酶抑制劑的哌啶衍生物
CN119143652B (zh) * 2024-09-13 2025-11-28 山东大学 一种手性2位双取代吲哚啉化合物及其合成方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201908293A (zh) * 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
WO2021163683A1 (en) * 2020-02-14 2021-08-19 President And Fellows Of Harvard College Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof

Also Published As

Publication number Publication date
WO2023129512A1 (en) 2023-07-06
EP4456892A4 (en) 2025-12-24
EP4456892A1 (en) 2024-11-06
CN119110724A (zh) 2024-12-10
US20250368638A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
JP2025503521A (ja) ニコチンアミドｎ－メチルトランスフェラーゼの二環式阻害剤、その組成物および使用
JP7138207B2 (ja) 幹細胞分化剤のスクリーニング方法
CN107027291B (zh) 用谷氨酰胺酶抑制剂的组合疗法
JP6889101B2 (ja) グルタミナーゼ阻害剤の結晶形態
JP6971239B2 (ja) グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
JP2018520352A (ja) アルギナーゼ活性を阻害するための組成物および方法
US11382908B2 (en) Compositions and methods for treating inflammatory bowel disease
US20250340549A1 (en) Bicyclic heteroaromatic inhibitors of nicotinamide n-methyltransferase, and compositions and uses thereof
JP7203018B2 (ja) クロモボックスタンパク質阻害剤およびその使用
KR20170132333A (ko) 글루타미나제 억제제에 의한 폐암의 치료
AU2018346331B2 (en) Small molecule inhibition of transcription factor SALL4 and uses thereof
CA3083228A1 (en) Small molecule degraders that recruit dcaft15
KR20190040302A (ko) 글루타미나제 억제제와의 병용 요법
CN109952293A (zh) Bmp信号转导的抑制、化合物、组合物及其用途
US12509430B2 (en) Inhibitors of nicotinamide N-methyltransferase, compositions and uses thereof
US10745400B2 (en) Inhibition of BMP signaling, compounds, compositions and uses thereof
US20210087143A1 (en) Agents for differentiating stem cells and treating cancer
US20210299109A1 (en) Agents for treating cancer and methods for identifying said agents
JP7696301B2 (ja) タンパク質分解のための化合物、組成物、および方法
JP2019535815A (ja) ｍＴＯＲ−ＤＥＰＴＯＲ相互作用の阻害剤及びその使用方法
CN107530302A (zh) Melk的水杨酸酯抑制剂和使用方法
HK40096682A (zh) 治疗疾病和病症的方法
HK40010184A (zh) 用谷氨酰胺酶抑制剂的组合疗法
HK1241722A1 (en) Crystal forms of glutaminase inhibitors
HK1241274B (zh) 用谷氨酰胺酶抑制剂的组合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251215